# Direct-to-Patient Clinical Trial Logistics: How to Deliver Investigational Medicines to the Front Door Source: https://fleetroot.com/blog/direct-to-patient-clinical-trial-logistics-how-to-deliver-investigational-medicines-to-the-front-door Published: 2026-10-01 · Category: Delivery management · Author: Fleetroot Team Directtopatient DtP clinical trial logistics moves investigational medicinal products IMPs from a qualified site, depot, or pharmacy to the participant’s home. The model reduces… Direct-to-patient (DtP) clinical trial logistics moves investigational medicinal products (IMPs) from a qualified site, depot, or pharmacy to the participant’s home. The model reduces site visits and can improve access and retention, but it also creates tighter control requirements. DtP is not ordinary last-mile delivery. The shipment must reach the correct participant, within the approved window, under the correct storage conditions, with complete documentation and a defensible audit trail. The main operating risks sit around chain of custody, chain of identity, cold chain control, failed delivery recovery, returns, and GxP-ready proof of delivery. This is where [healthcare logistics orchestration](https://fleetroot.com/solutions) becomes operationally important. ## The three direct-to-patient delivery models Sponsors generally use three DtP models. ![Three direct-to-patient clinical trial delivery models](https://cdn.marblism.com/kXWuk2x8iUY.webp) ### 1. Site-to-patient The investigator site receives and stores the IMP, then prepares and releases the shipment to the patient. This keeps direct site control and can fit smaller studies or markets with limited central dispensing, but it shifts packaging, coordination, accountability, and failed-delivery rework back to the site. ### 2. Depot-to-patient A central or regional depot stores, prepares, and dispatches patient-specific IMP directly to the participant. This model scales better for multinational trials because it centralizes inventory, packaging, and dispatch, but the depot, courier, and dispensing workflow still need to be qualified for the country and protocol. ### 3. Pharmacy-to-patient A delegated, specialty, or retail pharmacy receives or dispenses the IMP and arranges delivery to the patient. This can work where pharmacy dispensing is required, but it depends on strong control over pharmacy authorization, investigator oversight, identity verification, temperature handling, and dispensing records. The right model depends on the protocol, product, country, temperature range, patient population, and local rules. ## Why depot-to-patient is winning Depot-to-patient simplifies the network and scales better. It reduces the number of locations holding IMP, cuts site-level inventory, and standardizes kit assembly, label control, temperature monitoring, proof of delivery, and returns handling. It also reduces cross-border friction. Direct international delivery to each patient creates repeated customs events, while a regional depot can receive bulk inventory through a controlled import process and then distribute domestically or within an approved network. This does not remove customs risk, but it moves the highest-friction import activity to one controlled operating point. The model still has to account for country-specific authorization, import permits, labeling, depot or pharmacy licenses, data protection, and local rules for home delivery. Review the [EMA recommendations on decentralized clinical trial elements](https://health.ec.europa.eu/document/download/74386d75-e5fd-4d9c-9dfc-ec7d60758da9_en) and applicable national legislation before implementation. ## Protect chain of custody and chain of identity These controls are related but different. ### Chain of custody Chain of custody records who controlled the IMP and when, from manufacturer release through depot receipt, storage, courier handoff, delivery, returns, and final reconciliation. Each handoff needs a timestamped record, and electronic proof of delivery should capture shipment identifier, recipient confirmation, delivery date and time, and exception details. ### Chain of identity Chain of identity confirms that the correct patient receives the correct patient-specific product. This is critical in randomized and blinded trials, patient-specific kits, personalized medicines, and cell and gene therapies. The logistics system should use pseudonymized identifiers and connect patient ID, kit ID, shipment ID, and delivery event without exposing unnecessary clinical data to the courier. Common controls include barcode scanning, unique kit IDs, secure delivery codes, and recipient verification. ![Chain of custody and chain of identity in clinical trial delivery](https://cdn.marblism.com/g0IQyerdn9h.webp) The [FDA requirements for investigational drug records](https://www.fda.gov/drugs/investigational-new-drug-ind-application/federal-regulations-clinical-investigators) still apply. The delivery location changes. The accountability requirement does not. ## Design cold-chain lanes for the product Patient kits may use different temperature lanes: - Ambient - Refrigerated - Frozen - Ultra-low temperature Each lane requires qualified packaging and transport design. Controls typically include validated insulated shippers, pre-conditioned coolant, temperature data loggers, and time-definite delivery. Do not release shipments without a defined excursion process. If an excursion occurs, hold the product, record the shipment and temperature event, notify the sponsor or quality function, compare the event with stability data, obtain a documented disposition decision, replace the product if required, and update the accountability record. Do not instruct the patient to use or discard affected IMP without an approved decision. ![Cold-chain protection for cross-border clinical trial shipments](https://cdn.marblism.com/KF8ROZHb3cT.webp) ## Close the loop on failed delivery and returns A failed delivery is a quality and patient-support event, not only a courier exception. Common causes include patient unavailability, incorrect address details, damaged parcels, recipient verification failure, customs delay, temperature alerts, or delivery outside the approved window. The workflow should define who acts first and whether the product is returned, held, replaced, or destroyed. For unused or partially used IMP, the return process should document quantity, kit or batch ID, patient ID, return date, condition, reason, receipt confirmation, reconciliation result, and final disposition. Destruction still requires an approved procedure and certificate or equivalent evidence. ![Returns, electronic proof of delivery, and clinical trial logistics closure](https://cdn.marblism.com/F9GPWvf5HQ7.webp) ## Build GxP-ready proof of delivery A valid proof of delivery must do more than confirm a parcel reached an address. It must create a reconstructable audit trail. At minimum, capture shipment ID, kit ID, pseudonymized patient identifier, courier and handoff events, dispatch and delivery timestamps, recipient confirmation, delivery location, temperature record, exception status, return status, and user or system timestamps. The record should be searchable and exportable for monitoring, audits, and inspections. Use a logistics platform that provides [real-time tracking and operational visibility](https://fleetroot.com/features). Live status is useful. Complete history is required. ## FAQ ### What is direct-to-patient clinical trial logistics? It is the controlled delivery of investigational medicinal products from a site, depot, or pharmacy to a clinical trial participant’s home. ### Which DtP model is most scalable? Depot-to-patient is usually the most scalable because it centralizes inventory, packaging, dispatch, tracking, and returns. ### Who is responsible for IMP accountability? Responsibility remains with the sponsor and investigator even when logistics activities are delegated to vendors. For healthcare and life-sciences organizations, the objective is direct: deliver the right IMP to the right patient, within the right conditions, with a complete and auditable record.